{"preliminary_commentary":{"by_channel":{"x_thread":28,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04795661\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"localized resectable MSI/dMMR tumors","name":"IMHOTEP","nct_id":"NCT04795661","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imhotep-nct04795661. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMHOTEP","arms":[{"description":"Pembrolizumab prior to surgery","label":"Cohort Colorectal cancer (CRC)","type":"EXPERIMENTAL"},{"description":"Pembrolizumab prior to surgery","label":"Cohort Oesogastric cancer","type":"EXPERIMENTAL"},{"description":"Pembrolizumab prior to surgery","label":"Cohort Other cancer","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-10","type":"ESTIMATED"},"conditions":["Localized Resectable Tumor","MSI/dMMR"],"enrollment":{"count":240,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["MK3475 - Keytruda®"],"type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"Centre Leon Berard","official_title":"Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of complete pathological response (pCR) after surgery","timeFrame":"6 weeks after first injection"}],"references":[{"citation":"de la Fouchardiere C, Zaanan A, de Montfort A, Cohen R, Le Sourd S, Tougeron D, Soularue E, Dubreuil O, Williet N, Samalin-Scalzi E, Piessen G, Hautefeuille V, Jary M, Ben Abdelghani M, Evesque L, Rochigneux P, Blanc E, Perol D, Bibeau F, Coutzac C. Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP. J Clin Oncol. 2026 Jun;44(16):1520-1528. doi: 10.1200/JCO-25-02169. Epub 2026 Apr 14.","pmid":"41980235","type":"DERIVED"},{"citation":"Klute KA, Shah MA. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257044. doi: 10.6004/jnccn.2025.7044.","pmid":"40340830","type":"DERIVED"}],"start_date":{"date":"2021-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.","url":"https://clinicaltrials.gov/study/NCT04795661"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imhotep-nct04795661"}